Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-09-09

Clinical Trial Update: The Effects of RPL554 on Top of Standard COPD Reliever Medications [Phase 2]

View source ↗

Summary

Phase 2 trial update on the effects of RPL554 when added to standard COPD reliever medications; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RPL554 (RPL554)

Snippet

Sponsor: Verona Pharma plc | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED